Seminari / Workshop 2025
SEMINAR: Covalent drug discovery beyond Cys: targeting Lys, His, or Tyr
Prof. Maurizio Pellecchia
University of California Riverside
14:30 Saluti istituzionali - Prof. Mattia Sturlese, Dipartimento di Scienze del Farmaco - UniPD
14:35 LECTURE - Prof. Maurizio Pellecchia, University of California Riverside.
15:15 Sessione Q&A
Thursday 20 November 2025 - ore 14:30
Aula Ex-Biblioteca (primo piano) DSF
Info: mattia.sturlese@unipd.it
SEMINAR: Nanobodies or camelid antibody fragments: properties and applications
Mireille Dumoulin, Ph.D
NEPTUNS, Nanobodies to Explore Protein Structure and Functions, Centre for Protein Engineering; InBIOS, University of Liège, Belgium.
Lecture 1
1- What are Nanobodies? This part will explain how Nanobodies were discovered and give an overview of the unique properties of Nanobodies compared to those of conventional antibody fragments such as Fab, and ScFv.
2- How Nanobodies are generated and characterized? This lecture will introduce the different steps involved to generate and select Nanobodies against a given antigen, and to characterize them in term of affinity, specificity, epitope mapping, stability using various a range of technics including ELISA, SPR, Biolayer interferometry, ITC, fluorescence and circular dichroism
Lecture 2
How to engineer Nbs to further adapt their properties to the applications: creation of multivalent/multispecific Nanobodies, creation of chimeric Nbs (fusion with toxins, enzymes, etc.). We will discuss protein engineering strategies to improve the pharmacokinetics of Nbs and to label them for in vivo imaging.
Therapeutic, diagnostic and biotechnological application of Nanobodies, part 1
Lecture 3
Therapeutic, diagnostic and biotechnological applications of Nanobodies, part 2
When: from 10.11.2025 to 12.11.2025
Where: DSF - Department of Pharmaceutical and Pharmacological Sciences - Aula 6
Info: patrizia.polverinodelaureto@unipd.it
To enroll: https://medicina.elearning.unipd.it/course/view.php?id=7255
PROGRAMMA
14:00 Registrazione Workshop - Welcome coffee
14:30 OLIVENET in numeri: risultati e prospettive
Prof. Stefano dall’Acqua - Università degLi studi di Padova, Responsabile scientifico del progetto
Dott. Stefano Marabotto - Coordinatore della Rete Regionale Innovativa INNOSAP - INNOVAA
Dott. Nicola De Zordi - SAM Società Agricola Moldoi, Azienda partner di progetto
Dott.ssa Clizia Franceschi - Fomet SPA, Azienda partner di progetto
Prof. Massimiliano RinaldI - UniversItà di Parma
Prof.ssa Francisca Rodriguez - UniversItà di Porto
15:45 L’ESPERIENZA DEI RICERCATORI:
Dott.ssa Rohini Vijay Dhenge - Università dI Parma
Dott. Alberto Magnabosco - Università degLi Studi di Padova
16:45 Q&A: Domande e Risposte sul progetto a ricercatori e aziende
17:15 Momento di Networking
18:00 Conclusioni
Friday 6th June 2025 - 14:00 - 18:00 - Aula Ex-Biblioteca (primo piano) DSF
SEMINAR: Anticorpi monoclonali per Imaging e Terapia
Dott.ssa Raffaella Rossin, Vicepresidente dell'azienda farmaceutica olandese TagWorks, che ha di recente ricevuto l'autorizzazione della FDA per la Fase 1 del nuovo antitumorale.
Raffaella Rossin is a co-founder, and currently VP of Discovery, of Tagworks Pharmaceuticals, an innovative Dutch clinical biotech company developing improved cancer therapies based on proprietary Click-to-Release technology. Dr. Rossin achieved a PhD in Chemistry at the University of Padova in 2003. From 2003 to 2008, Dr. Rossin worked as Post-Doctoral fellow and Research Instructor at the Washington University School of Medicine In St. Louis Missouri, where she investigated many new radiolabeled compounds for tumor diagnosis and therapy. Dr. Rossin joined Philips Research in Eindhoven, The Netherlands, as Senior Radiochemist in 2008, before spinning out Tagworks with her colleague Marc Robillard in 2013.
Corso di Alta Formazione in Radiofarmacia - Corso di Dottorato in Scienze Farmaceutiche
Friday 9th May 2025 - 11:00 - Aula 1 DSF
SEMINAR: Radiofarmaci e Madicina Nucleare
Prof.ssa Paola Erba, Università di Milano Bicocca, University Medical Center Groningen, Paesi Bassi.
Prof. Paola Anna Erba is an Associate Professor in Nuclear Medicine and Diagnostic Imaging at the Medical Faculty of Bicocca University, and Chair of the Nuclear Medicine Department at ASST Papa Giovanni XXIII in Bergamo. She is also affiliated with the Department of Nuclear Medicine and Molecular Imaging at the University Medical Center Groningen, the Netherlands. Her research interests broadly cover the fields of infection, inflammation, and oncology. Her main area of focus is cardiovascular infections, where her work has led to the introduction of multimodality imaging in the clinical guidelines for infectious endocarditis and CIED infections. In oncology, her research centres on the validation of new targets/probes for radioimmunoscintigraphy/radioimmuno PET and radioimmunotherapy, as well as conducting translational, early-phase human clinical studies. She is an active member of the Italian Association of Nuclear Medicine (AIMN) and the European Association of Nuclear Medicine (EANM), where she currently serves as Education Chair of the European School of Multimodality Imaging and Therapy (ESMIT) and EANM President-Elect 2023–2025
Corso di Alta Formazione in Radiofarmacia - Corso di Dottorato in Scienze Farmaceutiche
Friday 9th May 2025 - 9:00 - Aula 1 DSF
SUMER SCHOOL VIU: “Exploring Nucleic Acids: from Biophysics to Molecular Biology”
Topics
- The biophysics of nucleic acids: Participants will tackle the main approaches for structure determination, as well as the analysis of the thermodynamic and kinetic aspects of nucleic acid folding.
- Nucleic acid-based nanotechnologies: Experts in the field will guide attendees through the latest advancements in biosensors and nanosystems based on nucleic acids, discussing their principles, advantages, and criticisms.
- New approaches in nucleic acids molecular biology: The course will cover the main sequencing techniques, and their applications, and it will provide an introduction to data analysis.
- Nucleic acids - a pharmaceutical perspective: These macromolecules will be examined from a dual perspective, both as pharmaceutical targets and as potential drugs.
Faculty
- Claudia Sissi, University of Padova
- Riccardo Rigo, University of Padova
- Francesco Mantegazza, University of Milano-Bicocca
- Elisabetta Groaz, KU Leuven
- Jurij Lah, University of Ljubljana
- Caterina Carraro, German Center for Neurodegenerative Diseases (DZNE)
- Lukas Trantirek, Central European Institute of Technology of Masaryk University)
- Leonard Prins, University of Padova
September 22-26, 2025 | Call for applications: January 15– May 15, 2025
SEMINAR: “To B or not to B” in Nucleic Acids Chemistry”
Dr. Naoki Sugimoto - Distinguished Professor of Frontier Institute for Biomolecular Engineering Research, Konan University, Japan.
Director of Frontier Institute for Biomolecular Engineering Research (FIBER) at Konan University From 2003 to 2024, his research interests focus on Biophysical Chemistry, Biomaterials, Bio-nano engineering, Molecular design, Biofunctional Chemistry, and Biotechnology. He has published more than 500 scientific papers, reviews, and books.
Thursday 30th January, 2:30 PM - "Aula Magna G. F. Azzone", Vallisneri building (Via Ugo bassi 58/B Padova)
